|
|
Volumn 3, Issue 11, 2004, Pages 899-900
|
|
Vioxx risk could signify trouble in class
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ATORVASTATIN;
CELECOXIB;
CERIVASTATIN;
CYCLOOXYGENASE 2 INHIBITOR;
DICLOFENAC;
ETORICOXIB;
NAPROXEN;
NONSTEROID ANTIINFLAMMATORY AGENT;
PARECOXIB;
PLACEBO;
ROFECOXIB;
VALDECOXIB;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
COLON POLYP;
DRUG MARKETING;
DRUG MECHANISM;
DRUG MEGADOSE;
DRUG SELECTIVITY;
DRUG TARGETING;
GASTROINTESTINAL HEMORRHAGE;
HEART INFARCTION;
HUMAN;
NOTE;
OSTEOARTHRITIS;
PRIORITY JOURNAL;
RHABDOMYOLYSIS;
RHEUMATOID ARTHRITIS;
RISK ASSESSMENT;
STROKE;
|
|
EID: 8844232711
PISSN: 14741776
EISSN: None
Source Type: Journal
DOI: 10.1038/nrd1560 Document Type: Note |
|
Times cited : (8)
|
|
References (0)
|